Drugs / KQ-2003 CAR T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06518876 | Aug 2024 → Dec 2027 expected | POEMS syndrome | Novatim Immune Therapeutics (Zhejiang) Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KQ-2003 CAR T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06518876 ↗ |
| Known as | KQ-2003 | “A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory POEMS Syndrome” NCT06518876 ↗ |
| Modality | Cell therapy | “simultaneously as a cellular therapy” NCT06518876 ↗ |
| Target | CD19 | “CD19 antigen molecules (anti-CD19 CAR)” NCT06518876 ↗ |